{
    "clinical_study": {
        "@rank": "156393", 
        "acronym": "BRAVO", 
        "arm_group": [
            {
                "arm_group_label": "Physician's choice", 
                "arm_group_type": "Active Comparator", 
                "description": "Physician may select from 4 active comparators"
            }, 
            {
                "arm_group_label": "niraparib", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomized 2:1 to receive niraparib 3 oral capsules (100mg) once daily for 21 continuous days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare progression-free survival (PFS)in patients with\n      advanced/metastatic breast cancer who have a BRCA gene change when treated with niraparib as\n      compared to those treated with physician's choice"
        }, 
        "brief_title": "A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Carcinoma of Breast", 
            "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", 
            "BRCA1 Gene Mutation", 
            "BRCA2 Gene Mutation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase III, randomized, open label, multicenter, controlled trial of niraparib\n      versus physician's choice in previously-treated, HER2 negative, germline BRCA\n      mutation-positive breast cancer patients. Niraparib is an orally active parp inhibitor.\n      Niraparib (in a 2:1 ratio) will be administered once daily continuously during a 21-day\n      cycle.  Physician's choice will be administered on a 21-day cycle. Health-related quality of\n      life will be measured.  The Safety and tolerability will be assessed by clinical review of\n      adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety\n      laboratory values."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Germline BRCA1 or BRCA2 mutation; patients with unknown BRCA status who meet NCCN\n             BRCA screening criteria will be screened for BRCA mutation.\n\n          2. Metastatic or locally advanced disease that is not amenable to resection or radiation\n             with curative intent.\n\n          3. Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer  patients\n             with no prior cytotoxic regimens for advanced or metastatic disease will only be\n             allowed if they relapsed during or within 12 months of (neo-) adjuvant cytotoxic\n             therapy that included a taxane and anthracycline, if not contraindicated.\n\n          4. Prior therapy should have included an anthracycline and a taxane (or contraindication\n             to those) in the neoadjuvant, adjuvant, or advanced/metastatic setting.\n\n             a. Hormone receptor positive patients must also have hormone resistant disease\n             (progression during at least one prior hormonal therapy) for which chemotherapy is\n             indicated.\n\n          5. ECOG performance status 0-2\n\n          6. Adequate bone marrow, kidney and liver function\n\n        Exclusion Criteria:\n\n          1. Patients with platinum resistant cancer\n\n          2. Symptomatic uncontrolled brain metastasis\n\n          3. Prior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a\n             5-year disease-free interval and normal CA125; Stage II ovarian cancer must have a\n             2-year disease-free interval and normal CA125\n\n          4. Known hypersensitivity to the components of niraparib\n\n          5. Invasive cancer other than ovarian cancer within 2 years (except basal or squamous\n             cell carcinoma of the skin that has been definitely treated)\n\n          6. Symptomatic uncontrolled brain metastasis\n\n          7. Pregnant or breast feeding patients\n\n          8. Immunocompromised patients\n\n          9. Known active Hepatitis B or C\n\n         10. Prior treatment with a PARP inhibitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "306", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905592", 
            "org_study_id": "PR-30-5010-C", 
            "secondary_id": "1307-BCG, BIG5-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "niraparib", 
                "description": "Until progression or unacceptable toxicity develops", 
                "intervention_name": "niraparib", 
                "intervention_type": "Drug", 
                "other_name": "formerly MK-4827"
            }, 
            {
                "arm_group_label": "Physician's choice", 
                "description": "Choice of 4 standard of care metastatic breast cancer chemotherapies", 
                "intervention_name": "Physician's choice", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", 
            "BRCA1 Gene Mutation", 
            "BRCA2 Gene Mutation", 
            "Parp Inhibitor", 
            "BRCA"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "Facing our risk of cancer empowered website", 
            "url": "http://www.facingourrisk.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tuscon", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Henderson", 
                        "country": "United States", 
                        "state": "Nevada"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Farmington", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Everett", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegam", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miskolc", 
                        "country": "Hungary"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reykjavik", 
                        "country": "Iceland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Hungary", 
                "Iceland", 
                "Netherlands", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients", 
        "other_outcome": {
            "description": "2 validated questionnaires to assess general quality of life and deterioration due to breast cancer", 
            "measure": "Health related quality of life", 
            "safety_issue": "No", 
            "time_frame": "End of study Oct 2015"
        }, 
        "overall_contact": {
            "email": "sagarwal@tesarobio.com", 
            "last_name": "Shefali Agarwal, MD", 
            "phone": "781-916-8375"
        }, 
        "overall_official": [
            {
                "affiliation": "Breast International Group", 
                "last_name": "Nicholas Turner, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hospital Universitari Vall d'Hebron", 
                "last_name": "Judith Balmana, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "European Organisation for Research and Treatment of Cancer", 
                "last_name": "David Cameron, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cedars-Sinai Medical Center", 
                "last_name": "William Audeh, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "EU: EMEA"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to compare progression-free survival as determined by central, blinded review, of patients with advanced/metastatic HER2-negative breast cancer who have a gBRCAmut when treated with niraparib as compared to those treated with physician's choice", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "After 96 PFS events (40%) have been documented.  Anticipated in about 16 months from first patient enrolled"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To compare overall survival of patients with advanced/metastatic HER2-negative breast cancer who have a gBRCAmut when treated with niraparib as compared to those treated with physician's choice", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "54 months after the first patient is enrolled"
        }, 
        "source": "Tesaro, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Breast International Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Myriad Genetic Laboratories, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "US Oncology Research", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Sarah Cannon", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Facing Our Risk of Cancer Empowered (FORCE)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Tesaro, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}